Sensus Healthcare Inc (STU:5TX)

Q2 2026 Sensus Healthcare Inc Earnings Call Transcript

Aug 13, 2026 / 08:30 PM GMT

Release Date Price: €2.7

Transcript 10-Q8-K

Key Points

Positve

Sensus Healthcare Inc (SRTS) secured 8 equipment orders that were delayed in Q2 due to third-party financing issues, and these have since been approved and will be recognized as revenue in Q3.
The company's commercial momentum strengthened during Q2, with a stronger pipeline, increased inbound interest, and engagement with a broader range of customers including larger physician groups and health systems.
The new dedicated CPT codes for SRT are driving adoption, as physicians now have greater reimbursement clarity and are moving from 'whether' to 'how' to incorporate SRT into their practices.
Sensus Healthcare Inc (SRTS) is seeing growing international interest, particularly in Australia, which has the highest skin cancer rate globally, presenting a significant market opportunity.
The company is expanding its recurring revenue streams through the Fair Deal Agreement program and CensusLink software, with all new customers adopting CensusLink and inside sales efforts targeting existing customers.

Negative

Sensus Healthcare Inc (SRTS) experienced a significant revenue decline in Q2 2026, with revenue of $2.3 million compared to $7.3 million in the prior year period, due to lower unit sales.
The company faced a financing issue with a third-party bank that failed to complete approvals on time, preventing the recognition of 19 units in Q2 and leading to a decision to no longer work with that bank.
Gross margin decreased to 34.8% from 39.7% in the prior year, driven by product mix including higher international shipments with lower average selling prices and costs associated with new system placements.
Adjusted EBITDA was negative $3 million in Q2 2026, worse than the negative $1.8 million in Q2 2025, indicating continued operational losses.
The company recorded a net loss of $8.7 million in Q2 2026, including a $5.7 million valuation allowance against deferred tax assets, and cash decreased to $15.2 million from $18.3 million at the end of Q1.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SRTS.OQ - Sensus Healthcare Inc
Q2 2026 Sensus Healthcare Inc Earnings Call
Aug 13, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the Census Healthcare's 2026 Financial Results Conference Call.

All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero.

After today's presentation, there will be an opportunity to ask questions.

To ask a question, you may press star then one on your telephone keypad. To withdraw your questions, please press star then two.

Please note this event is being recorded. I would now like to turn the conference over to Alex Sharif with New Street Investor Relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.